2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Non-Biological Therapies, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Genomics, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

2116 Sonic: Escalated inpatient ramp-up of sonrotoclax in CLL/SLL and MCL

Jennifer J. Huang, MD, PhD, Laura Samples, MD2, Jenna Voutsinas, MPH3, Grace Bishop4, Ryan Basom5, Margo Fredericks6, Stephanie Louie7, Christine Crider8, Mehrdad Shakib Azar9, Ted Gooley, PhD10, Qian Wu, PhD11, Mengyang Di, MD, PhD12, Paul S Martin, MD13, Stephen Douglas Smith, MD14, Brian G Till, MD15, Ajay Gopal, MD16, Ryan C Lynch, MD17, Chaitra Ujjani, MD18, Mazyar Shadman, MD, MPH19
1 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
2 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
3 Fred Hutchinson Cancer Center, Seattle, Washington, United States
4 Fred Hutchinson Cancer Center, Seattle, Washington, United States
5 Fred Hutchinson Cancer Center, Seattle, Washington, United States
6 Fred Hutchinson Cancer Center, Seattle, Washington, United States
7 Fred Hutchinson Cancer Center, Seattle, Washington, United States
8 Fred Hutchinson Cancer Center, Seattle, Washington, United States
9 Fred Hutchinson Cancer Center, Seattle, Washington, United States
10 Fred Hutchinson Cancer Center, Seattle, Washington, United States
11 Fred Hutchinson Cancer Center, Seattle, Washington, United States
12 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
13 University of Washington, Seattle, Washington, United States
14 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
15 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
16 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
17 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
18 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
19 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States

Introduction

Sonrotoclax is a second-generation BCL-2 inhibitor without evidence of the development of clinical tumor lysis syndrome (TLS) in combinatorial clinical studies. A prolonged ramp-up schedule to reach the target dose is used to decrease the risk of TLS. There is a critical need for a rapid but safe ramp-up strategy to expedite achievement of the target dose, and sonrotoclax is an excellent candidate for investigating an escalated ramp-up schedule.

Methods

SONIC is a single-institution, phase 2 clinical trial (NCT06839053) conducted at Fred Hutch Cancer Center/University of Washington that included patients (pts) with treatment-naïve or relapsed/refractory (R/R) CLL/SLL or R/R mantle cell lymphoma (MCL) with the primary objective of examining the safety and tolerability of an escalated 4-day inpatient ramp-up of sonrotoclax.

Participants who were not refractory to Bruton tyrosine kinase (BTK) inhibitors (Cohort A) received 3 cycles of zanubrutinib for debulking while pts who were refractory to BTK inhibitors (Cohort B) received weekly rituximab x 4. Following debulking, pts were admitted for daily dose escalation of 2mg, 5mg, 20mg, and 80mg on Days 1-4 and then discharged with the plan to receive the 160 mg dose as an outpatient on Day 5. The final dose ramp-up to 320mg occurred on Day 12 +/- 2 days. Labs were drawn pre-, 4 and 8 hours after the first 4 ramp-up doses, and 1L intravenous fluids was given after the first sonrotoclax dose. Participants were subsequently treated with concurrent zanubrutinib for 1 year (Cohort A) or rituximab for 6 months (Cohort B).

TLS risk groups were categorized as low risk (all lymph nodes [LN] <5 cm and absolute lymphocyte count [ALC] <25 x 109/L), intermediate risk (1+ LN 5-10 cm or ALC ≥25 x 109/L), and high risk (1+ LN ≥10cm or [ALC ≥25 x 109/L and any LN ≥5 cm]). Sonrotoclax-specific TLS risk was categorized as high risk (per above high-risk criteria) and low risk (all other scenarios). TLS was defined per Howard criteria.

Results

Planned enrollment of 20 pts has been completed. Seventeen pts (85%) were enrolled in Cohort A and 3 (15%) in Cohort B. Nineteen pts (95%) had CLL/SLL, and 1 (5%) had MCL. Median age was 65 years old, and 45% (n=9) were male. Majority of pts were White (95%; n=19), and none were Hispanic or Latino.

At study enrollment, 35% of pts (n=7) were classified as low risk for TLS, 65% (n=13) as intermediate risk, and none as high risk. Median ALC was 32.5 x 109/L (interquartile range [IQR]: 5.2–52.3 x 109/L).

Seventeen pts (85%) have completed inpatient rapid ramp-up of sonrotoclax, with 2 pts currently undergoing debulking therapy and 1 withdrawn prior to ramp-up. Following debulking and just prior to sonrotoclax initiation, TLS risk classification improved for some pts, with 55% of pts (n=11) in the low- and 30% (n=6) in the intermediate-risk group for TLS. None were at high risk for TLS. Median ALC was 10.9 x 109/L (IQR: 3.4–42 x 109/L).

All 17 pts achieved the target dose of 80mg by Day 4, and all pts subsequently received 160 mg dosing on Day +5 and 320 mg dosing on Day 12 (+/-2 days). Three pts (17.6%) received their Day 5 160mg dosing inpatient for clinical monitoring. There were no occurrences of either laboratory or clinical TLS. Laboratory abnormalities that did not meet TLS criteria included hyperphosphatemia (>4.5 mg/dL) (30%, n=6). There were no hyperuricemia (>8.0 mg/dL), hyperkalemia (>6.0 meq/L), or hypocalcemia (serum calcium <7.0 mg/dL or ionized calcium <1.12 mg/dL) events.

The most common any-grade treatment emergent adverse events (TEAE) during the study were fatigue, petechiae, and rash (47%, n=9), all Grade 1 or 2 events. The most common Grade ≥3 TEAEs was neutropenia (15.8%), and there were no other Grade ≥3 TEAEs that occurred in >5% of pts.

Conclusion

A 4-day inpatient escalated ramp-up of sonrotoclax successfully enabled all patients to increase their dose from 2mg to 80mg without the development of laboratory or clinical TLS and with an expected safety profile. This included participants at low and intermediate risk for TLS at baseline and at time of sonrotoclax initiation after debulking with zanubrutinib or rituximab. As the initial 20 participants met the pre-specified safety endpoint, an expansion cohort of 10 additional patients was added to better define efficacy and will be presented at the meeting. We are planning to further explore the safety and feasibility of this escalated ramp-up strategy in the outpatient setting.
Jennifer J. Huang, MD, PhD: BMS - Research Funding; BeOne Medicines - Research Funding; AbbVie - Research Funding; Merck - Research Funding; AbbVie - Consultancy (Includes expert testimony)